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operation had failure of the re-repair result-
ing from recurrent mitral regurgitation in 5
and hemolysis in 1.
We are grateful to the Editor for the
opportunity to further clarify these points.
Rakesh M. Suri, MD, DPhil
Hartzell V. Schaff, MD
Cardiovascular Surgery
Mayo Clinic College of Medicine
Rochester, Minn
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Limitations with aprotinin in thoracic
aortic surgery: Understanding the
clinical outcome beyond bleeding
To the Editor:
I read with great interest the recent article
by Dr Sedrakyan and colleagues1 detailing
their experience with aprotinin in thoracic
aortic surgery, using a retrospective case-
control matching analysis (n  168 [1995-
2003]: deep hypothermic circulatory arrest
(DHCA) 64.3%–67.9%). The authors con-
clude in their article that there is American
Heart Association level II evidence for
aprotinin in thoracic aortic surgery.
I have the following questions for the
authors of this excellent study:
1. What was the reexploration rate for
bleeding in this case-control series?
Did antifibrinolytic exposure make
any difference? This outcome vari-
able is an important determinant of
mortality after thoracic aortic sur-
gery.2 It would be useful to know
whether aprotinin was associated
with a lower take-back rate.
2. Were anesthetic technique and an-
esthetic drug doses equivalent in
both groups? This is an important
determinant of postoperative venti-
lation time. Was this potential con-
founder considered before conclud-
ing that aprotinin is associated with
a decrease in total ventilation time?
3. Were the clinical outcomes, includ-
ing renal failure and dysfunction,
equivalent in the subgroup with
DHCA? Our group has recently re-
ported that aprotinin may be associ-
ated with renal dysfunction after
DHCA.3 Does a mixed thoracic aor-
tic cohort explain the differences in
these studies?
4. Were there criteria for antifibrino-
lytic choice in this cohort (eg, pre-
vious aprotinin exposure; level of
renal impairment)? When was the
aprotinin administered (eg, before
skin incision or after dissection
and cannulation for cardiopulmo-
nary bypass)? It would be useful to
understand the dosing style of apro-
tinin in this study.
5. Were there any hypersensitivity re-
actions to aprotinin?4 Were there
any cases of unexpected vascular
thrombosis?5
I look forward to input from the authors.
Again, I congratulate them for a most valu-
able article on this challenging topic.
John G. T. Augoustides, MD, FASE
Department of Anesthesiology and Critical Care
Hospital of the University of Pennsylvania
Philadelphia, PA
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Reply to the Editor:
We appreciate Dr Augoustides’ kind com-
ments regarding our article.1 We are very
much aware of the important contributions
he and his colleagues have made on the
topic at hand.
We provide the following specific re-
sponses to the insightful comments and
questions raised in Dr. Augoustides’ letter.
1. Three patients required reexplora-
tion for bleeding—1 in the aprotinin
group and 2 in the control group.
2. Anesthesia was by a balanced nar-
cotic/inhalation technique in both
groups.
3. Renal failure occurred in 3 patients
in the control group and 2 in the
aprotinin group.
4. Aprotinin was administered after
the skin incision. It is our policy to
avoid aprotinin in the rare circum-
stance of recent prior aprotinin ex-
posure.
5. There were no clinically appreciated
hypersensitivity reactions to aproti-
nin. There were no cases of unex-
pected vascular thrombosis.
In sum, the points raised by Dr Augous-
tides are all very cogent. On each point,
there was, in our study, no evidence of
adverse aprotinin-related outcome.
Artyrom Sedrakayan, MD
Maryann Tranquilli, RN
John A. Elefteriades, MD
Department of Cardiothoracic Surgery
Yale University School of Medicine,
New Haven, CT
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Unilateral as well as bilateral
infiltrates should remain part of the
definition of pulmonary graft
dysfunction
To the Editor:
We read with interest the article by Oto and
associates1 in the December 2006 issue of
the Journal. The authors underestimate the
importance of unilateral infiltrates. We dis-
agree with the statement, “only bilateral
infiltrates should be used as part of the
definition of primary graft dysfunction” de-
spite their convincing statistical methods.
We explain why.
The guidelines of pulmonary graft dys-
function (PGD)2 and validation3 thereof is
for the clinician to make sense of the data
and standardize reporting. The emphasis by
the consensus committee on PGD was on
providing a definition that could also help
in management and prognosis.2 PGD is a
biological process of reperfusion–ischemic
injury redefined with respect to alveolar–
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